| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
14,310,000 |
| Market
Cap: |
33.49(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.12 - $2.77 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Eledon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis. Co.'s lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a biological target. AT-1501 is engineered to improve safety and provide pharmacokinetic, pharmacodynamic and dosing advantages. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,927,937 |
1,927,937 |
1,927,937 |
3,907,869 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,597 |
| Total People Bought |
1 |
1 |
1 |
2 |
| Total Buy Transactions |
1 |
1 |
1 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Turkel Catherine C. |
President |
• – – |
2018-09-05 |
4 |
B |
$3.97 |
$3,193 |
I/I |
805 |
805 |
1.91 |
- |
|
| Kuwahara Jon |
See Remarks |
• – – |
2018-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
11,250 |
11,250 |
|
- |
|
| Turkel Catherine C. |
President |
• – – |
2018-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
44,519 |
|
- |
|
| Flesher Gregory J. |
Chief Executive Officer |
• • – |
2018-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
30,700 |
146,556 |
|
- |
|
| Flesher Gregory J. |
Chief Executive OfficerOfficer |
• • – |
2017-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
56,897 |
|
- |
|
| Chimovits Erez |
Director |
– • – |
2017-05-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,537,110 |
|
- |
|
| Turkel Catherine C. |
Chief Development OfficerOffic |
• – – |
2017-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,408 |
|
- |
|
| Ocampo Christine |
See RemarksOfficer |
• – – |
2017-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
11,580 |
|
- |
|
| Katkin Keith |
Director |
– • – |
2017-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,119 |
|
- |
|
| Flesher Gregory J. |
Chief Executive Officer |
• • – |
2017-05-10 |
4 |
B |
$9.99 |
$589,000 |
D/D |
58,959 |
115,856 |
2.81 |
- |
|
| Turkel Catherine C. |
Chief Development Officer |
• – – |
2017-05-10 |
4 |
B |
$9.99 |
$110,999 |
D/D |
11,111 |
24,519 |
2.74 |
- |
|
| Ocampo Christine |
See Remarks |
• – – |
2017-05-10 |
4 |
B |
$9.99 |
$100,000 |
D/D |
10,010 |
21,590 |
2.74 |
- |
|
| Orbimed Israel Biofund Gp Limited Partnership |
Director |
– • • |
2017-05-09 |
4 |
A |
$0.00 |
$0 |
I/I |
2,537,110 |
2,537,110 |
|
- |
|
| Buckley Stephen Jr. |
|
– • – |
2016-03-15 |
4 |
B |
$5.74 |
$45,920 |
D/D |
8,000 |
11,000 |
0.01 |
- |
|
| Morrison Jodie Pope |
President and CEO |
• • – |
2016-01-08 |
4 |
OE |
$0.63 |
$32,449 |
D/D |
28,015 |
57,566 |
|
- |
|
| Buckley Stephen Jr. |
|
– • – |
2015-11-11 |
4 |
B |
$11.25 |
$33,750 |
D/D |
3,000 |
3,000 |
0.01 |
- |
|
| Mcbride John S. |
Chief Operating Officer |
• – – |
2015-09-21 |
4 |
AS |
$14.01 |
$189,135 |
D/D |
(13,500) |
0 |
|
- |
|
| Mcbride John S. |
Chief Operating Officer |
• – – |
2015-09-21 |
4 |
OE |
$4.19 |
$56,565 |
D/D |
13,500 |
13,500 |
|
- |
|
| Kalowski Lee |
Chief Financial Officer |
• – – |
2015-09-08 |
4 |
AS |
$13.13 |
$61,291 |
D/D |
(4,668) |
40,953 |
|
- |
|
| Kalowski Lee |
Chief Financial Officer |
• – – |
2015-09-02 |
4 |
AS |
$12.96 |
$27,968 |
D/D |
(2,158) |
45,621 |
|
- |
|
| Morrison Jodie Pope |
President and CEO |
• • – |
2015-07-29 |
4 |
OE |
$0.63 |
$9,411 |
D/D |
10,564 |
29,551 |
|
- |
|
| Morrison Jodie Pope |
President and CEO |
• • – |
2015-07-29 |
4 |
AS |
$13.70 |
$7,727 |
D/D |
(564) |
19,551 |
|
- |
|
| Morrison Jodie Pope |
President and CEO |
• • – |
2015-07-28 |
4 |
AS |
$13.70 |
$164,400 |
D/D |
(12,000) |
19,551 |
|
- |
|
| Morrison Jodie Pope |
President and CEO |
• • – |
2015-07-28 |
4 |
OE |
$1.58 |
$18,960 |
D/D |
12,000 |
31,551 |
|
- |
|
| Morrison Jodie Pope |
President and CEO |
• • – |
2015-07-22 |
4 |
OE |
$0.63 |
$10,624 |
D/D |
10,000 |
19,551 |
|
- |
|
89 Records found
|
|
Page 2 of 4 |
|
|
0.15 (6.85%) 
